Original Article

Effects of Familial Hypercholesterolemia on Major Adverse Cardiac and Cerebrovascular Events in Patients with Premature Coronary Artery Disease: A Retrospective Cohort Study

Abstract

Background: Evaluating the impact of familial hypercholesterolemia (FH) on the occurrence of major adverse cardiac and cerebrovascular events (MACCE) in patients with premature coronary artery disease.
Methods: This retrospective cohort study was conducted at Tehran Heart Center, between 2004 and 2011. 3907 patients with acute coronary syndrome (ACS) who underwent coronary angiography were collected from registry systems. The patients were divided into "Unlikely FH" and "Probable FH" using a modified and simplified version of the Dutch Lipid Clinic Network (DLCN) criteria. After a 10-year follow-up, different components of MACCE between the two groups were evaluated.
Results: Data from 3206 premature coronary artery disease patients with baseline LDL values were extracted. 2558 (79.8%) patients were categorized into the Unlikely FH group, and 648 (20.2%) patients were in the probable FH group. In the unlikely FH group, 745 (29.1%) patients experienced at least one of the MACCE events. In the probable FH group, 193 (29.7%) experienced at least one MACCE event. The difference between groups did not reach the level of significance (p>0.05). The mortality rate in the unlikely FH group was 6.9% (n=179), while in the probable FH group, the mortality rate was 7.8% (n=51) (p<0.05).
Conclusions: In the present study, patients with probable FH pose a higher risk regarding mortality than unlikely FH patients.

1. Bouhairie VE, Goldberg AC. Familial hypercholesterolemia. Cardiol Clin. 2015;33:169–79.
2. Singh S, Bittner V. Familial hypercholesterolemia—epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17:482.
3. Onorato A, Sturm AC. Heterozygous familial hypercholesterolemia. Circulation. 2016;133:e587–9.
4. Li S, Zhang HW, Guo YL, Wu NQ, Zhu CG, Zhao X, et al. Familial hypercholesterolemia in very young myocardial infarction. Sci Rep. 2018;8:8861.
5. Mortensen MB, Kulenovic I, Klausen IC, Falk E. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: prevalence, risk factor burden, and impact on age at presentation. J Clin Lipidol. 2016;10:1145–52.e1.
6. Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, et al. Familial hypercholesterolemia among young adults with myocardial infarction. J Am Coll Cardiol. 2019;73:2439–50.
7. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S9–17.
8. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90a.
9. Huang CC, Charng MJ. Genetic diagnosis of familial hypercholesterolemia in Asia. Front Genet. 2020;11:833.
10. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168:1–14.
11. Nanchen D, Gencer B, Muller O, Auer R, Aghlmandi S, Heg D, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698–709.
12. Abbasi SH, Kassaian SE, Sadeghian S, Karimi A, Saadat S, Peyvandi F, et al. Introducing the Tehran Heart Center’s Premature Coronary Atherosclerosis Cohort: THC-PAC Study. J Tehran Heart Cent. 2015;10:34–42.
13. Sun D, Cao YX, Li S, Guo YL, Wu NQ, Gao Y, et al. A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia. Clin Cardiol. 2019;42:988–94.
14. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956–64.
15. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152–60.
16. De Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016;133:1067–72.
17. Sawhney JPS, Prasad SR, Sharma M, Madan K, Mohanty A, Passey R, et al. Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India. Indian Heart J. 2019;71:118–22.
18. Rerup SA, Bang LE, Mogensen UM, Engstrøm T, Jørgensen E, Pedersen F, et al. The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. Am Heart J. 2016;181:35–42.
19. Al-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, Almahmeed W, Rashed W, Ridha M, et al. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol. 2018;12:685–92.e2.
Files
IssueVol 20 No 1 (2025) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jthc.v20i1.19221
Keywords
Familial Hypercholesterolemia MACCE Premature Coronary Artery Disease Acute Coronary Syndrome
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Shahi S, Gholamizadeh N, Dasdar S, Hosseini K, Jalali A, Lotfi Tokaldani M, Tajdini M. Effects of Familial Hypercholesterolemia on Major Adverse Cardiac and Cerebrovascular Events in Patients with Premature Coronary Artery Disease: A Retrospective Cohort Study. Res Heart Yield Transl Med. 2025;20(1):47-54.